{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T01:18:49Z","timestamp":1779239929020,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jpba.2023.115955","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T12:35:41Z","timestamp":1704371741000},"page":"115955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Application of advanced high resolution mass spectrometric techniques for the analysis of losartan potassium regarding known and unknown impurities"],"prefix":"10.1016","volume":"240","author":[{"given":"Laura","family":"Backer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Buschmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Kinzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fritz","family":"S\u00f6rgel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Scherf-Clavel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Holzgrabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2023.115955_bib1","unstructured":"Fachinformation: Losartan-AbZ 100 mg Filmtabletten. https:\/\/www.abz.de\/assets\/products\/de\/label\/Losartan-AbZ%20100%20mg%20Filmtabletten%20-%203.pdf?pzn=9154992. Accessed November 28, 2023."},{"key":"10.1016\/j.jpba.2023.115955_bib2","unstructured":"World Health Organization. Model List of Essential Medicines. 2021;22nd List. https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2021.02. Accessed November 28, 2023."},{"key":"10.1016\/j.jpba.2023.115955_bib3","unstructured":"European Medicines Agency. EMA reviewing medicines containing valsartan from Zhejiang Huahai following detection of an impurity. (July 5, 2018). https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/ema-reviewing-medicines-containing-valsartan-zhejiang-huahai-following-detection-impurity_en.pdf. Accessed November 28, 2023."},{"key":"10.1016\/j.jpba.2023.115955_bib4","unstructured":"European Medicines Agency: Valsartan. review of impurities extended to other sartan medicines. (September 21, 2018). https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/valsartan-review-impurities-extended-other-sartan-medicines_en.pdf. Accessed November 28, 2023."},{"key":"10.1016\/j.jpba.2023.115955_bib5","unstructured":"Co-ordination Group for Mutual Recognition and Decentralised Procedures-Human. Risk of azido-impurity in losartan-containing medicinal products. (September 23, 2021). https:\/\/www.bfarm.de\/SharedDocs\/Downloads\/DE\/Arzneimittel\/Pharmakovigilanz\/PSUSAS\/m-r\/octreotid_cmdh_Anlage-3.pdf?__blob=publicationFile. Accessed November 28, 2023."},{"key":"10.1016\/j.jpba.2023.115955_bib6","unstructured":"Co-ordination Group for Mutual Recognition and Decentralised Procedures-Human. Azido impurity in irbesartan confirmed positive in bacterial mutagenicity test. (April 2021). https:\/\/www.dls.gov.ua\/wp-content\/uploads\/2021\/07\/\u0414\u043e\u0434\u0430\u0442\u043e\u043a-\u041b\u0438\u0441\u0442-CMDh_430_2021.pdf. Accessed November 28, 2023."},{"key":"10.1016\/j.jpba.2023.115955_bib7","unstructured":"PharmNet.Bund. Ver\u00f6ffentlichte Lieferengpassmeldungen Losartan. https:\/\/anwendungen.pharmnet-bund.de\/lieferengpassmeldungen\/faces\/public\/meldungen.xhtml. Accessed November 28, 2023."},{"key":"10.1016\/j.jpba.2023.115955_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113425","article-title":"Risk assessment report of potential impurities in cetirizine dihydrochloride","volume":"189","author":"Leistner","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115955_bib9","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1021\/op300179u","article-title":"An efficient, commercially viable, and safe process for preparation of losartan potassium, an angiotensin II receptor antagonist","volume":"16","author":"Madasu","year":"2012","journal-title":"Org. Process Res Dev."},{"key":"10.1016\/j.jpba.2023.115955_bib10","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ICH Topic Q3A (R2) Impurities in new Drug Substances. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-3-r2-impurities-new-drug-substances-step-5_en.pdf. Accessed November 28, 2023."},{"key":"10.1016\/j.jpba.2023.115955_bib11","unstructured":"Losartan potassium European Pharmacopoeia 11.0. Council of Europe, Strasbourg, France, 2022."},{"key":"10.1016\/j.jpba.2023.115955_bib12","unstructured":"Losartan potassium USP43-NF 38. U.S. Food and Drug Administration, Silver Spring, Maryland, USA, 2020."},{"key":"10.1016\/j.jpba.2023.115955_bib13","unstructured":"Losartan potassium Japanese pharmacopoeia 18. Pharmaceuticals and Medical Devices Agency, Tokyo, Japan, 2021."},{"key":"10.1016\/j.jpba.2023.115955_bib14","first-page":"1","article-title":"Charged aerosol detector response modeling for fatty acids based on experimental settings and molecular features: a machine learning approach","volume":"13","author":"Pawellek","year":"2021","journal-title":"Crit. Rev. Anal."},{"key":"10.1016\/j.jpba.2023.115955_bib15","article-title":"What is the role of current mass spectrometry in pharmaceutical analysis?","author":"Khalikova","year":"2023","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.jpba.2023.115955_bib16","unstructured":"SwissMedic. Genotoxische Substanzen in Sartanen. https:\/\/www.swissmedic.ch\/dam\/swissmedic\/de\/dokumente\/bewilligungen\/labor_omcl\/sartans-testingmethod-31_pv_185.pdf.download.pdf\/31_PV_185_Genotoxische_Substanzen_in_Sartanen.pdf. Accessed November 28, 2023."},{"key":"10.1016\/j.jpba.2023.115955_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114300","article-title":"The determination of two analogues of 4-(azidomethyl)-1, 1\u2032-biphenyl as potential genotoxic impurities in the active pharmaceutical ingredient of several sartans containing a tetrazole group","volume":"205","author":"Jire\u0161","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115955_bib18","unstructured":"Guo C., Xu Y., Wang W., et al., Inventors; Shandong Institute for Food and Drug Control, assignee. Method for simultaneously measuring MB-X and AZBC impurities in irbesartan raw materials and preparations. June 10, 2021."},{"key":"10.1016\/j.jpba.2023.115955_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.arabjc.2023.104951","article-title":"Development and validation of an LC-MS\/MS method for simultaneous determination of three organic azido impurities in tetrazole-containing sartans","volume":"16","author":"Wichitnithad","year":"2023","journal-title":"Arab J. Chem."},{"key":"10.1016\/j.jpba.2023.115955_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcoa.2021.100012","article-title":"Impurity profiling of bisoprolol fumarate by liquid chromatography-high-resolution mass spectrometry: a combination of targeted and untargeted approaches using a synthesis reaction matrix and general unknown comparative screening","volume":"1","author":"Wohlfart","year":"2021","journal-title":"J. Chromatogr. Open"},{"key":"10.1016\/j.jpba.2023.115955_bib21","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1021\/ac403385y","article-title":"Comparison of information-dependent acquisition, SWATH, and MSAll techniques in metabolite identification study employing ultrahigh-performance liquid chromatography\u2013quadrupole time-of-flight mass spectrometry","volume":"86","author":"Zhu","year":"2014","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2023.115955_bib22","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1002\/jssc.200900092","article-title":"General unknown screening procedure for the characterization of human drug metabolites in forensic toxicology: applications and constraints","volume":"32","author":"Sauvage","year":"2009","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.jpba.2023.115955_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2105-11-148","article-title":"In silico fragmentation for computer assisted identification of metabolite mass spectra","volume":"11","author":"Wolf","year":"2010","journal-title":"BMC Bioinform."},{"key":"10.1016\/j.jpba.2023.115955_bib24","unstructured":"Wasserchemische Gesellschaft. Anwendung des Non-Target-Screenings mittels LC-ESI-HRMS in der Wasseranalytik. 2019. https:\/\/www.gdch.de\/fileadmin\/downloads\/Netzwerk_und_Strukturen\/Fachgruppen\/Wasserchemische_Gesellschaft\/NTS-Leitfaden_DE_s.pdf. Accessed November 28, 2023."},{"key":"10.1016\/j.jpba.2023.115955_bib25","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/0731-7085(96)01740-2","article-title":"Comparison of liquid chromatography, capillary electrophoresis and super-critical fluid chromatography in the determination of Losartan Potassium drug substance in Cozaar\u00ae tablets","volume":"14","author":"Williams","year":"1996","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115955_bib26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jchromb.2007.09.007","article-title":"Monitoring phospholipids for assessment of matrix effects in a liquid chromatography\u2013tandem mass spectrometry method for hydrocodone and pseudoephedrine in human plasma","volume":"859","author":"Ismaiel","year":"2007","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2023.115955_bib27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0731-7085(99)00004-7","article-title":"Identification of losartan degradates in stressed tablets by LC-MS and LC-MS\/MS","volume":"20","author":"Zhao","year":"1999","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115955_bib28","unstructured":"Method of analysis N-methyl-2-pyrrolidone. US Food and Drug Administration Center for Veterinary Medicine. 2011. https:\/\/www.fda.gov\/media\/83088\/download. Accessed November 28, 2023."},{"key":"10.1016\/j.jpba.2023.115955_bib29","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ICH guideline Q3C (R8) on impurities: guideline for residual solvents. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/ich-guideline-q3c-r8-impurities-guideline-residual-solvents-step-5_en.pdf. Accessed November 28, 2023."},{"key":"10.1016\/j.jpba.2023.115955_bib30","unstructured":"Inclusion of Substances of Very High Concern in the Candidate List (Decision of the European Chemicals Agency). https:\/\/echa.europa.eu\/documents\/10162\/2d6cdfd7-e924\u201345fa-85d4\u20134450a7b4bf5a. Accessed November 28, 2023."},{"key":"10.1016\/j.jpba.2023.115955_bib31","unstructured":"European Pharmacopoeia 11.0, chapter 2.4.24. Identification and control of residual solvents. Council of Europe, Strasbourg, France, 2022."},{"key":"10.1016\/j.jpba.2023.115955_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2022.107112","article-title":"Losartan metabolite EXP3179 is a unique blood pressure-lowering AT1R antagonist with direct, rapid endothelium-dependent vasoactive properties","volume":"147","author":"Sauge","year":"2022","journal-title":"Vasc. Pharm."},{"key":"10.1016\/j.jpba.2023.115955_bib33","unstructured":"Co-ordination Group for Mutual Recognition and Decentralised Procedures-Human. Report from the CMDh meeting held on 21\u201322 June 2022. (July 18, 2022). https:\/\/www.hma.eu\/fileadmin\/dateien\/Human_Medicines\/CMD_h_\/CMDh_pressreleases\/2022\/CMDh_press_release_-_June_2022_01.pdf. Accessed November 28, 2023."},{"key":"10.1016\/j.jpba.2023.115955_bib34","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.3390\/molecules25041009","article-title":"Reactive & efficient: Organic azides as cross-linkers in material sciences","volume":"25","author":"Schock","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jpba.2023.115955_bib35","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cplett.2005.01.060","article-title":"Gas phase UV absorption cross-sections for a series of amides","volume":"404","author":"Chakir","year":"2005","journal-title":"Chem. Phys. Lett."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523007240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523007240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:37:19Z","timestamp":1760002639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523007240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":35,"alternative-id":["S0731708523007240"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115955","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of advanced high resolution mass spectrometric techniques for the analysis of losartan potassium regarding known and unknown impurities","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115955","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115955"}}